EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation

Xiao-Yan You, Xiang-Yang Li, Hui Wang, Guo-Ping Zhao

Cell Proliferation · 2026-04 · 59 (4)

DOI: 10.1111/cpr.70118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Proliferation, online erschienen am 27.08.2025. Verfasst von Xiao-Yan You und 3 weiteren Autor:innen. Beteiligte Einrichtung: Henan Engineering Research Center of Food Microbiology, College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, Chin…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptides, Organoids, Liver. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Priority Research Program of the Chinese Academy of Sciences, Major Project of Haihe Laboratory of Synthetic Biology, Tianjin Synthetic Biotechnology Innovation Capacity Improvement Projects.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Progressive non‐alcoholic fatty liver disease (NAFLD) may culminate in severe complications, including fibrosis, cirrhosis and hepatocellular carcinoma, yet therapeutic breakthroughs remain elusive, necessitating novel pharmacological strategies. Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist clinically approved for type 2 diabetes and obesity management, has demonstrated pleiotropic effects in preclinical NAFLD models. In this study, we investigated semaglutide's therapeutic efficacy and mechanisms in a human liver organoids (hLOs) model of NAFLD. Utilising microengineered array chips, human induced pluripotent stem cells (hiPSCs) were differentiated into hLOs with functional hepatic properties. NAFLD pathology was induced via free fatty acid (FFA) exposure, recapitulating disease hallmarks such as steatosis, inflammatory cytokine elevation and fibrogenic activation. Semaglutide treatment at 50 nM significantly attenuated lipid deposition caused by FFAs and reduced triglyceride levels by 8‐fold and cholesterol levels by 1.8‐fold. It also inhibited the expression of pro‐inflammatory markers (IL‐6, IL‐8, TNF‐α) by about 1.5–2 fold and increased the level of lipolytic genes by about 45%. These findings elucidate the therapeutic potential of semaglutide in attenuating key NAFLD‐associated pathologies and establish a robust in vitro platform for preclinical drug evaluation. The study provides critical insights into targeted NAFLD interventions and supports the translation of GLP‐1‐based therapies into clinical practice, addressing an unmet need in hepatology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseGlucagon-Like PeptidesOrganoidsLiverHumansInduced Pluripotent Stem CellsCell Differentiation

Stichwörter der Autor:innen

array chipdrug assessmentnon‐alcoholic fatty liverorganoidsemaglutide

Substanzen

Glucagon-Like Peptides

Autor:innen und Institutionen

  • Henan Engineering Research Center of Food Microbiology, College of Food and Bioengineering, Henan University of Science and Technology, Luoyang, China.
  • Master Lab for Innovative Application of Nature Products, National Center of Technology Innovation for Synthetic Biology, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China.
  • Haihe Laboratory of Synthetic Biology, Tianjin, China.
  • School of Life Sciences, Faculty of Medicine, Tianjin Key Laboratory of Function and Application of Biological Macromolecular Structures, Tianjin University, Tianjin, China.
  • CAS-Key Laboratory of Synthetic Biology, CAS Center for Excellence in Molecular Plant Sciences, Institute of Plant Physiology and Ecology, Chinese Academy of Sciences, Shanghai, China.
  • CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.

Förderung

  • Strategic Priority Research Program of the Chinese Academy of Sciences
  • Major Project of Haihe Laboratory of Synthetic Biology
  • Tianjin Synthetic Biotechnology Innovation Capacity Improvement Projects
  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation

Zitieren

APA

You, X. Y., Li, X. Y., Wang, H., & Zhao, G. P. (2026). Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation, 59(4). https://doi.org/10.1111/cpr.70118

Vancouver

You XY, Li XY, Wang H, Zhao GP. Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation. Cell Proliferation. 2026;59(4). doi:10.1111/cpr.70118

BibTeX
@article{You2026,
  author = {You, Xiao-Yan and Li, Xiang-Yang and Wang, Hui and Zhao, Guo-Ping},
  title = {Development of NAFLD ‐Specific Human Liver Organoid Models on a Microengineered Array Chip for Semaglutide Efficacy Evaluation},
  journal = {Cell Proliferation},
  year = {2026},
  volume = {59},
  number = {4},
  doi = {10.1111/cpr.70118}
}
Kostenlos starten →